Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2011. The report details a specific share repurchase transaction executed on November 3, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 1,200,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,381.5 pence per share; lowest price paid was 1,340.0 pence per share.
- Treasury Holdings (Settled): 511,539,248 shares (9.18% of total issued share capital).
- Treasury Holdings (Including Unsettled): 514,627,927 shares (10.17% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,060,874,372 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,200,000 shares on November 3, 2011. This transaction increased the proportion of shares held in Treasury from the prior level to 9.18% of issued capital (or 10.17% of voting rights including unsettled shares).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the 1,200,000 shares purchased using the reported price range (1,340.0 to 1,381.5 pence).
- Confirm the updated total issued share capital and the specific impact on earnings per share (EPS) in subsequent financial reports.
- Check the settlement status of the shares to confirm the final Treasury holding percentage.
- Review the remaining authorization for share buybacks under the May 5, 2011 shareholder mandate.